Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.55 |
| ▸ | KIT | P10721 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.41 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2805862 | 0.99 | FLT3 (0.54) | FLT3KITKMT2AMAPK10VNN1 | |
| SCHEMBL2804906 | 0.88 | FLT3 (0.53) | FLT3KITKMT2AMAPK10VNN1 | |
| SCHEMBL185903 | 0.87 | KIT (0.44) | FLT3KITMAPK10PTK2HDAC3 | |
| SCHEMBL2780905 | 0.84 | FLT3 (0.57) | FLT3KITKMT2AMAPK10PTK2 | |
| Trifluoroacetic Acid SCHEMBL185821 | 0.83 | FLT3 (0.49) | FLT3KITKMT2AMAPK10VNN1 | |
| Trifluoroacetic Acid SCHEMBL185939 | 0.83 | FLT3 (0.49) | FLT3KITKMT2AMAPK10VNN1 | |
| Trifluoroacetic Acid SCHEMBL2807127 | 0.83 | FLT3 (0.49) | FLT3KITKMT2AMAPK10VNN1 | |
| SCHEMBL2808253 | 0.80 | KIT (0.38) | FLT3KITMAPK10HDAC3HDAC1 | |
| SCHEMBL185082 | 0.80 | KIT (0.38) | FLT3KITMAPK10HDAC3HDAC1 | |
| SCHEMBL2808251 | 0.80 | KIT (0.38) | FLT3KITMAPK10HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | FLT3 632/4885KIT 989/4885KMT2A 4682/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | FLT3 632/4885KIT 989/4885KMT2A 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.